951 related articles for article (PubMed ID: 16855053)
1. Metabolism of endosulfan-alpha by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4.
Casabar RC; Wallace AD; Hodgson E; Rose RL
Drug Metab Dispos; 2006 Oct; 34(10):1779-85. PubMed ID: 16855053
[TBL] [Abstract][Full Text] [Related]
2. Stereoselective metabolism of endosulfan by human liver microsomes and human cytochrome P450 isoforms.
Lee HK; Moon JK; Chang CH; Choi H; Park HW; Park BS; Lee HS; Hwang EC; Lee YD; Liu KH; Kim JH
Drug Metab Dispos; 2006 Jul; 34(7):1090-5. PubMed ID: 16581944
[TBL] [Abstract][Full Text] [Related]
3. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.
Heyn H; White RB; Stevens JC
Drug Metab Dispos; 1996 Sep; 24(9):948-54. PubMed ID: 8886603
[TBL] [Abstract][Full Text] [Related]
4. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
Ramírez J; Innocenti F; Schuetz EG; Flockhart DA; Relling MV; Santucci R; Ratain MJ
Drug Metab Dispos; 2004 Sep; 32(9):930-6. PubMed ID: 15319333
[TBL] [Abstract][Full Text] [Related]
5. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A
Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348
[TBL] [Abstract][Full Text] [Related]
6. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes.
Hijazi Y; Boulieu R
Drug Metab Dispos; 2002 Jul; 30(7):853-8. PubMed ID: 12065445
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies.
Hamaoka N; Oda Y; Hase I; Asada A
Br J Anaesth; 2001 Apr; 86(4):540-4. PubMed ID: 11573629
[TBL] [Abstract][Full Text] [Related]
9. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
[TBL] [Abstract][Full Text] [Related]
10. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.
Rehmel JL; Eckstein JA; Farid NA; Heim JB; Kasper SC; Kurihara A; Wrighton SA; Ring BJ
Drug Metab Dispos; 2006 Apr; 34(4):600-7. PubMed ID: 16415119
[TBL] [Abstract][Full Text] [Related]
11. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA.
Jacobson PA; Green K; Birnbaum A; Remmel RP
Cancer Chemother Pharmacol; 2002 Jun; 49(6):461-7. PubMed ID: 12107550
[TBL] [Abstract][Full Text] [Related]
13. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation.
Chang Y; Fang WB; Lin SN; Moody DE
Basic Clin Pharmacol Toxicol; 2011 Jan; 108(1):55-62. PubMed ID: 20825389
[TBL] [Abstract][Full Text] [Related]
14. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
Lalovic B; Phillips B; Risler LL; Howald W; Shen DD
Drug Metab Dispos; 2004 Apr; 32(4):447-54. PubMed ID: 15039299
[TBL] [Abstract][Full Text] [Related]
15. Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes.
Yanagihara Y; Kariya S; Ohtani M; Uchino K; Aoyama T; Yamamura Y; Iga T
Drug Metab Dispos; 2001 Jun; 29(6):887-90. PubMed ID: 11353758
[TBL] [Abstract][Full Text] [Related]
16. Examination of purported probes of human CYP2B6.
Ekins S; VandenBranden M; Ring BJ; Wrighton SA
Pharmacogenetics; 1997 Jun; 7(3):165-79. PubMed ID: 9241656
[TBL] [Abstract][Full Text] [Related]
17. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
Hyland R; Roe EG; Jones BC; Smith DA
Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
[TBL] [Abstract][Full Text] [Related]
18. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
Faucette SR; Hawke RL; Lecluyse EL; Shord SS; Yan B; Laethem RM; Lindley CM
Drug Metab Dispos; 2000 Oct; 28(10):1222-30. PubMed ID: 10997944
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide.
May-Manke A; Kroemer H; Hempel G; Bohnenstengel F; Hohenlöchter B; Blaschke G; Boos J
Cancer Chemother Pharmacol; 1999; 44(4):327-34. PubMed ID: 10447581
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of levo-alpha-Acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites.
Oda Y; Kharasch ED
J Pharmacol Exp Ther; 2001 Apr; 297(1):410-22. PubMed ID: 11259570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
